Skip to the main content.

2 min read

Tim Lowery Appointed Interim CEO of KBI and Selexis

Durham, North Carolina (November 09, 2022)  -- KBI Biopharma & Selexis (“KBI”) today announced the appointment of JSR Life Sciences President Tim Lowery as interim CEO, effective immediately. Mr. Lowery, who joined JSR in 1996, brings extensive management and life sciences experience. He will continue his roles as Chairman of KBI Biopharma and Board Chair of Selexis SA.

KBI and JSR have launched a search process to identify a permanent CEO.


Tim Lowery Professional Biography

President, JSR Life Sciences
Tim Lowery joined JSR in 1996. Since then, he has supported JSR in several capacities, including as CEO of MBLI, a JSR Life Sciences company. Tim was instrumental in establishing JSR’s life sciences business, spearheading the company’s M&A activities, and global expansion of life science operations.

As President, he is responsible for the development and integration of global strategies among all the JSR Life Sciences companies, which include Crown Bioscience, KBI Biopharma, Inc., MBL and Selexis SA.

Mr. Lowery holds a bachelor's degree in Mechanical Engineering from North Carolina State University and an MBA from Duke University’s Fuqua School of Business.

About JSR Life Sciences, LLC

A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit

About KBI Biopharma, Inc.

KBI Biopharma, Inc. is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at

About Selexis SA

Selexis SA is a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. As part of a comprehensive drug development process, Selexis technologies shorten development timelines and reduce manufacturing risks. More information is available at